Blue Companion
BLUE COMPANION provides digital services for health through private-public partnership projects. They also offer CRO services by designing and conducting clinical studies, as well as providing project management and study management services. Their privileged therapeutic domains are neurodegenerative and neuromuscular diseases, as well as ophthalmology.
BLUECompanion also designs, deploys and manages customised integrated ICT platforms to treat and monitor on quasi real time different data sources (auto-evaluation questionnaires, wearable devices, robotic interfaces, mobile phones…).
Learn more: www.bluecompanion.eu
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
December 13, 2025
Mind Health With 53,000 new cases diagnosed each year, lung cancer is the deadliest cancer in France, according to data from the National Cancer Institute. Three-quarters of cases are detected at an advanced stage, which reduces the chances of recovery. The importance of screening is therefore crucial. In this field, the combination of low-dose CT […]
November 27, 2025
Med City News Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost […]
November 27, 2025
Trial Site News Clinical trial reporting of treatment efficacy is the foundation of public trust in medicine. Yet pharmaceutical companies often report efficacy measured as a relative risk reduction (RRR) while omitting the more relevant absolute risk reduction (ARR). This statistical sleight of hand can make clinically insignificant benefits look spectacular! Consider a simple example A risk is […]